Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced today that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
A key development is the commercialization of withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, which is now available as a subscription-based research platform for the global biomedical and drug development community. This represents a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
The upcoming financial report will be closely watched by investors and industry observers as it will provide the first glimpse of revenue from the withZeta.ai platform, potentially validating the company’s strategy of monetizing its AI capabilities beyond internal drug development. The integration of AI into drug discovery and development has been a growing trend in the biopharmaceutical industry, with companies like Lantern aiming to reduce costs and accelerate timelines.
Lantern’s focus on precision oncology, particularly its pipeline targeting specific genetic subtypes, positions it within a rapidly evolving field where personalized medicine is becoming standard. The HARMONIC trial for LP-300 in never-smoker lung adenocarcinoma patients addresses a distinct population with high unmet need. Additionally, the development of LP-184 for pediatric CNS cancers through Starlight Therapeutics highlights the company’s efforts to expand into areas with limited treatment options.
The financial results on May 15 will provide insight into the company’s cash runway and spending on clinical trials, which are critical for investors assessing the company’s ability to advance its pipeline. The operational updates will also shed light on enrollment progress and next milestones for key trials.
For more information, visit the company’s newsroom at https://ibn.fm/LTRN.
